Wednesday, July 8, 2026

biotech · Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · JSPR

Jasper Therapeutics

Jasper Therapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Redwood City, CA, US HQ
44 Employees
Public company Type
JSPR · NYSE Ticker
Company details
Status
Public
HQ
Redwood City, CA, US
Employees
44
Programs
13
Drugs
13
Patents
1
Intelligence · Clinical Programs

Jasper Therapeutics projects

13 ClinicalTrials.gov programs sponsored by Jasper Therapeutics.

Jasper Therapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Nicotine patch

    Jasper Therapeutics

    Nicotine Dependence

    phase 3 small molecule active

    1 trial
  2. Briquilimab

    Jasper Therapeutics

    Chronic Urticaria

    phase 2 small molecule active

    1 trial
  3. Briquilimab

    Jasper Therapeutics

    Chronic Inducible Urticaria

    phase 2 small molecule terminated

    1 trial
  4. Briquilimab

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial
  5. Briquilimab

    Jasper Therapeutics

    Urticaria Chronic

    phase 2 small molecule active

    1 trial
  6. EPINEPHRINE , Briquilimab

    Jasper Therapeutics

    Chronic Inducible Urticaria

    phase 2 small molecule active

    1 trial
  7. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    SCID

    phase 2 mab terminated

    1 trial
  8. JSP-CP-011

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial
  9. Briquilimab

    Jasper Therapeutics

    Allergic Asthma

    phase 1 small molecule terminated

    1 trial
  10. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    MYELODYSPLASTIC SYNDROME; MDS

    phase 1 mab active

    1 trial
  11. JSP-CP-012

    Jasper Therapeutics

    allergic asthma

    phase 1 other active

    1 trial
  12. JSP191

    Jasper Therapeutics

    Lower-risk Myelodysplastic Syndrome

    phase 1 small molecule terminated

    1 trial
  13. Nelfinavir and Omeprazole

    Jasper Therapeutics

    Healthy Volunteers

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Jasper Therapeutics have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.